Genmab (GMAB) Reports Epcoritamab Trial Shows Progression-Free Survival Improvement
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 3d ago
0mins
Source: stocktwits
- Trial Results: Genmab's late-stage trial of Epcoritamab showed an improvement in progression-free survival for certain patients with relapsed or refractory diffuse large B-cell lymphoma, although overall survival did not reach statistical significance, indicating potential efficacy in specific patient populations.
- Disease Context: Diffuse large B-cell lymphoma is the most common and aggressive type of non-Hodgkin lymphoma, characterized by the rapid proliferation of large B-lymphocytes, often presenting as fast-growing masses or swollen nodes, accompanied by symptoms such as fever, night sweats, and weight loss, highlighting the severity of the disease.
- Regulatory Engagement Plan: Genmab intends to engage with regulatory authorities to discuss next steps for Epcoritamab, demonstrating the company's proactive approach to advancing the drug towards potential approval, despite current results not fully meeting expectations.
- Stock Price Reaction: Following the announcement, Genmab's shares fell by 4%, reflecting market caution regarding the trial results, which may impact investor confidence in the company's future prospects.
Analyst Views on GMAB
Wall Street analysts forecast GMAB stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for GMAB is 38.50 USD with a low forecast of 26.00 USD and a high forecast of 48.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
7 Analyst Rating
5 Buy
2 Hold
0 Sell
Moderate Buy
Current: 33.850
Low
26.00
Averages
38.50
High
48.00
Current: 33.850
Low
26.00
Averages
38.50
High
48.00
About GMAB
Genmab A/S is a Denmark-based international biotechnology company. It specializes in the creation and development of antibody therapeutics for the treatment of cancer. The Company is the creator of the approved antibodies: DARZALEX (daratumumab) for the treatment of certain multiple myeloma indications, Kesimpta for the treatment of adults with relapsing forms of multiple sclerosis, TEPEZZA (teprotumumab) for the treatment of thyroid eye disease and FASPRO, for the treatment of adult patients with certain multiple myeloma indications. The first approved Genmab created therapy Arzerra, approved for the treatment of certain chronic lymphocytic leukemia indications, is available in Japan and is also available in other territories via compassionate use or oncology access programs. Genmab develops a broad clinical and pre-clinical product pipeline, and owns four antibody technologies, DuoBody bispecific platform, HexaBody platform, DuoHexaBody platform & HexElect platform.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
